Table 3.
Summary of adverse events
| Number of sessions | TOCE | TOCE + HAIC | ||||||
|---|---|---|---|---|---|---|---|---|
| 15 | 36 | |||||||
| Grade | ||||||||
| Haematological toxicity | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
| White blood cell decreased | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil count decreased | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-haematological toxicity | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
| AST increased | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT increased | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PT-INR increased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Creatinine increased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anorexia | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Nausea | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Vomiting | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fever | 1 | 0 | 0 | 0 | 5 | 0 | 0 | 0 |
| Diarrhea | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fatigue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urticaria | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Abdominal pain | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TOCE transarterial oily chemoembolization, TACE transarterial chemoembolization, HAIC hepatic arterial infusion chemotherapy, PT-INR prothrombin time-international normalized ratio